An open-label, interventional, single-center, prospective clinical study to evaluate the efficacy and safety of "AHPL/AYTAB/1514" in patients suffering from halitosis.

Objectives: The main objective of the study was to assess the efficacy and safety of AHPL/AYTAB/1514 tablet in patients suffering from halitosis.

Methodology: Fifty four patients were recruited in the study. Patients were advised to take maximum two tablets or at least one tablet four times a day (depending on tolerability of the drug) orally for 60 days.